title: A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
abstract: Sorafenib, an oral multi-kinase inhibitor, has been approved for treatment of advanced renal-cell and hepatocellular carcinoma (HCC). However, 20% of HCC patients taking sorafenib are forced to withdraw due to adverse effects within one month after administration. Orally administered sorafenib is oxidatively metabolized, predominantly by cytochrome P450 3A4 (CYP3A4), in small-intestinal mucosa or liver. We aimed to characterize the CYP3A4-mediated metabolism of sorafenib in HCC patients and explore the contribution of the major metabolite sorafenib N-oxide to adverse effects and therapeutic efficacy. We have therefore developed a method for quantitative determination of sorafenib and its N-oxide in the present study. To optimize the preanalytical procedure, we initially ascertained the solubility of the analytes. Because they are lipophilic, solvents containing more than 40% acetonitrile were required for efficient recovery. The pretreatment procedure that we ultimately developed consists of acetonitrile precipitation, followed by extraction using octadecyl silyl-silica gel to eliminate water-soluble and hydrophilic components of serum. Application of this procedure before HPLC enabled accurate and reproducible quantitation of analytes in a linear range from 0.03 to 30 μg/mL. After characterizing the peaks in the HPLC-ultraviolet chromatogram obtained from a medicated patient by LC-tandem mass spectrometry, we applied this method to HCC patients taking sorafenib, showing large inter-individual differences in the pharmacokinetic profile. In conclusion, our assay system should be useful for follow-up of patients taking sorafenib and for exploring the association between the pharmacokinetics of sorafenib and its N-oxide and the adverse effects or therapeutic efficacy.
authors.affiliation: Department of Pharmaceutical Sciences, Tohoku University Hospital.
authors.forename: Miki
authors.initials: M
authors.lastname: Shimada
authors.forename: Hoshimi
authors.initials: H
authors.lastname: Okawa
authors.forename: Takahiro
authors.initials: T
authors.lastname: Maejima
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yanagi
authors.forename: Kanehiko
authors.initials: K
authors.lastname: Hisamichi
authors.forename: Masaki
authors.initials: M
authors.lastname: Matsuura
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Akasaka
authors.forename: Masami
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: Yasuteru
authors.initials: Y
authors.lastname: Kondo
authors.forename: Tooru
authors.initials: T
authors.lastname: Shimosegawa
authors.forename: Masaru
authors.initials: M
authors.lastname: Mori
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Maekawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Suzuki
authors.forename: Nariyasu
authors.initials: N
authors.lastname: Mano
mesh_terms: D000097:Acetonitriles / Q000737:chemistry; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000188:drug therapy*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D006801:Humans; D007477:Ions; D008113:Liver Neoplasms / Q000097:blood* / Q000188:drug therapy*; D013058:Mass Spectrometry; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry; D010087:Oxides / Q000097:blood* / Q000737:chemistry; D010671:Phenylurea Compounds / Q000097:blood* / Q000737:chemistry; D012015:Reference Standards; D012995:Solubility; D012996:Solutions; D000077157:Sorafenib; D014466:Ultraviolet Rays
chemical_list: D000097:Acetonitriles; D007477:Ions; D010087:Oxides; D010671:Phenylurea Compounds; D012996:Solutions; D009536:Niacinamide; D000077157:Sorafenib; C032159:acetonitrile